Anteris Technologies Ltd. and v2vmedtech, inc. announced they have reached concept lock on the first phase of the system. TEER is fast becoming the primary intervention for patients with mitral and tricuspid valve disease, however current marketed systems have limitations that often prevent optimal procedural outcomes or limit eligibility for certain patient groups. The VClipTM design intent is to address these unmet needs and provide better outcomes for patients.